— Financing led by Fidelity Management & Research Company with participation from RiverVest Venture Partners, Lightchain Capital, LYZZ Capital, Abingworth, Intermediate Capital Group (ICG), Tybourne Capital Management, Aisling Capital Management, and other top-tier life sciences investors — — Proceeds will fund the ongoing pivotal T-RRex trial in relapsed/refractory T-ALL/T-LBL — — WU-CART-007 achieved 91% overall...| Wugen
Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an overall response rate of 91% and composite complete remission rate of 73% in heavily pretreated patients with R/R T-ALL/LBL The global pivotal Phase 2 T-RRex Study will evaluate WU-CART-007 in pediatric and adult patients ST. LOUIS,... The post Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cel...| Wugen
ST. LOUIS, MO and SAN DIEGO, CA, Feb. 26, 2025 – Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, today announced the appointment of Jim Faulkner, Ph.D., as chief technology officer, initially serving on an interim basis. “Jim brings a specialized skill set...| Wugen
— Data Support Start of First Pivotal Trial for an Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell Therapy in Pediatric and Adult Patients — ST. LOUIS, MO and SAN DIEGO, CA, Dec. 5, 2024 – Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, today... The post Wugen to Present Clinical Data at the 2024 ASH Annual Meeting Ahead of Pivotal Trial Launch of Off-the-Shelf...| Wugen
— First Pivotal Trial for an Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell Therapy to Begin in First Quarter 2025 — — The Global Study Will Evaluate WU-CART-007 in Pediatric and Adult Patients — ST. LOUIS, MO and SAN DIEGO, CA, Nov. 12, 2024 – Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell... The post Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CAR...| Wugen
ST. LOUIS, MO and SAN DIEGO, CA, Nov. 12, 2024 – Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, today announced the appointment of Cherry T. Thomas, M.D. as the company’s chief medical officer. “Cherry joins Wugen at our most critical inflection point... The post Cherry T. Thomas, M.D., Joins Wugen as Chief Medical Officer, Bringing Cell Therapy Expertise Acros...| Wugen
— Researchers Shared Findings Including a Clinically Manageable Safety Profile and Anti-leukemic Activity with WU-CART-007 in Patients with R/R T-ALL/LBL and Previously Treated with Existing Therapies — — U.S. Biotech Wugen to Initiate Follow-Up Study Exploring Its Anti-CD7, Off-the-Shelf, Allogeneic CAR-T Cell Therapy in Pediatric and Minimal Residual Disease (MRD) Patients in Q424 — —... The post Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Hi...| Wugen
— Researchers to Present New Phase 2 Data Showing Safety and Anti-Leukemic Activity with WU-CART-007 and Additional New Findings for this Investigational, Off-the-Shelf Allogeneic CAR-T Cell Therapy — — Company to Initiate Follow-Up Study in Q4 2024 with WU-CART-007 in Pediatric and Minimal Residual Disease (MRD) Patients — — Will Share New Data for WU-NK-101,... The post Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Pres...| Wugen
The Woodlands, TX, and St. Louis, MO, March 14, 2024/ Cision / – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced the signing of an agreement... The post Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen’s O...| Wugen
Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancers ROCKVILLE, MD, and ST LOUIS, MO, January 30, 2024 — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics... The post MaxCyte and Wugen Sign Strategic Platform License to Ex...| Wugen